Amount of qualified clients: CDEC reviewed the uncertainty in the quantity of sufferers with moderately intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some individuals who are categorised as acquiring delicate or moderate sickness could possibly have a significant bleeding https://hemgenix38183.blogolize.com/hemgenix-secrets-75058262